Shizuoka, Japan

Naoki Taka



 

Average Co-Inventor Count = 4.6

ph-index = 2

Forward Citations = 11(Granted Patents)


Location History:

  • Gotenba, JP (2008)
  • Shizuoka, JP (2014 - 2015)

Company Filing History:


Years Active: 2008-2015

Loading Chart...
Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Naoki Taka: Innovator in Cancer Treatment

Introduction

Naoki Taka is a prominent inventor based in Shizuoka, Japan. He has made significant contributions to the field of cancer treatment through his innovative research and development of new compounds. With a total of 3 patents to his name, Taka's work focuses on aminopyrazole derivatives that have the potential to revolutionize cancer therapies.

Latest Patents

Taka's latest patents include a method for treating cancer that involves administering a pharmaceutically effective amount of a composition containing a compound represented by a specific formula. This compound is designed to target and inhibit fibroblast growth factor receptor (FGFR) family kinases in cancer tissues. The detailed chemical structure includes various groups that enhance its effectiveness in treating cancer.

Career Highlights

Throughout his career, Naoki Taka has worked with notable companies such as Chugai Seiyaku Kabushiki Kaisha and F. Hoffmann-La Roche AG. His experience in these organizations has allowed him to collaborate with leading experts in the pharmaceutical industry, further advancing his research.

Collaborations

Some of Taka's notable coworkers include Masayuki Ohmori and Kyoko Takami. Their collaborative efforts have contributed to the development of innovative solutions in cancer treatment.

Conclusion

Naoki Taka's work in the field of cancer treatment exemplifies the impact of innovative research on healthcare. His contributions through patents and collaborations highlight the importance of continued advancements in medical science.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…